Drug Trial Radar · NCT06579105
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
406
Actual
Start
Oct 8, 2024
Primary completion
Dec 19, 2025
Study completion Dec 19, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Placebo (placebo matching AZD5004 film-coated tablet)Drug
Placebo film-coated tablet (matching AZD5004)
AZD5004Drug
AZD5004 film-coated tablet, once daily during 26 weeks
SemaglutideDrug
3-14 mg tablets of Semaglutide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: Baseline to Week 26
Locations
97 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Mobile, Alabama
Research Site
Sheffield, Alabama
Research Site
Vestavia Hills, Alabama
Research Site
Tucson, Arizona
Research Site
Little Rock, Arkansas
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Sacramento, California
Research Site
Waterbury, Connecticut
Research Site
Lake City, Florida
Research Site
Largo, Florida
Research Site
Ocoee, Florida
Research Site
Orlando, Florida
Research Site
Decatur, Georgia
Research Site
Savannah, Georgia
Research Site
Lombard, Illinois
Research Site
Potomac, Maryland
Research Site
Boston, Massachusetts
Research Site
Roslindale, Massachusetts
Research Site
Farmington Hills, Michigan
Research Site
Gulfport, Mississippi
Research Site
Kansas City, Missouri
Research Site
Omaha, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Albuquerque, New Mexico
Research Site
Binghamton, New York
Research Site
Durham, North Carolina
Research Site
Greensboro, North Carolina
Research Site
Rocky Mount, North Carolina
Research Site
Statesville, North Carolina
Research Site
Wilmington, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Fargo, North Dakota
Research Site
Beachwood, Ohio
Research Site
Cincinnati, Ohio
Research Site
Medford, Oregon
Research Site
West Chester, Pennsylvania
Research Site
Gaffney, South Carolina
Research Site
Bristol, Tennessee
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.